2022 Q3 Form 10-Q Financial Statement
#000135657622000057 Filed on August 08, 2022
Income Statement
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
Revenue | $177.4M | $170.1M | $152.5M |
YoY Change | 19.46% | 20.32% | 16.48% |
Cost Of Revenue | $25.88M | $20.46M | $17.93M |
YoY Change | 43.09% | -18.26% | 19.91% |
Gross Profit | $151.5M | $149.6M | $134.6M |
YoY Change | 16.18% | 28.63% | 16.03% |
Gross Profit Margin | 85.41% | 87.97% | 88.24% |
Selling, General & Admin | $112.3M | $100.5M | $90.46M |
YoY Change | 55.92% | 44.5% | 47.19% |
% of Gross Profit | 74.15% | 67.17% | 67.22% |
Research & Development | $19.55M | $16.39M | $20.84M |
YoY Change | -0.51% | 6.02% | -39.21% |
% of Gross Profit | 12.91% | 10.95% | 15.49% |
Depreciation & Amortization | $21.78M | $21.56M | $21.36M |
YoY Change | 226.22% | 225.98% | 224.06% |
% of Gross Profit | 14.38% | 14.41% | 15.87% |
Operating Expenses | $131.9M | $116.9M | $111.3M |
YoY Change | 43.83% | 37.5% | 16.25% |
Operating Profit | -$1.523M | $11.35M | $1.967M |
YoY Change | -104.67% | -66.74% | -85.11% |
Interest Expense | $1.724M | $1.810M | $1.942M |
YoY Change | -70.9% | -66.89% | -68.15% |
% of Operating Profit | 15.95% | 98.73% | |
Other Income/Expense, Net | $1.079M | -$22.00K | $12.76M |
YoY Change | -129.61% | -99.24% | -658.25% |
Pretax Income | -$444.0K | $11.32M | $14.72M |
YoY Change | -101.53% | -63.75% | 34.71% |
Income Tax | -$2.193M | $3.459M | -$10.89M |
% Of Pretax Income | 30.55% | -73.99% | |
Net Earnings | $1.749M | $7.865M | $25.62M |
YoY Change | -91.89% | -66.85% | 349.88% |
Net Earnings / Revenue | 0.99% | 4.63% | 16.8% |
Basic Earnings Per Share | $0.03 | $0.15 | $0.48 |
Diluted Earnings Per Share | $0.03 | $0.14 | $0.43 |
COMMON SHARES | |||
Basic Shares Outstanding | 53.50M shares | 53.43M shares | 53.33M shares |
Diluted Shares Outstanding | 55.03M shares | 61.40M shares | 61.41M shares |
Balance Sheet
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $391.8M | $360.8M | $312.2M |
YoY Change | -11.73% | -11.97% | -20.17% |
Cash & Equivalents | $111.5M | $173.4M | $115.7M |
Short-Term Investments | $280.3M | $187.4M | $196.5M |
Other Short-Term Assets | $24.85M | $21.41M | $22.37M |
YoY Change | -19.05% | -36.54% | 27.11% |
Inventory | $83.17M | $84.86M | $88.80M |
Prepaid Expenses | |||
Receivables | $164.1M | $158.1M | $145.1M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $663.9M | $625.1M | $568.5M |
YoY Change | -0.67% | -2.21% | -2.99% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $15.87M | $16.32M | $17.22M |
YoY Change | -65.92% | -65.08% | -54.64% |
Goodwill | $117.4M | $115.4M | $115.4M |
YoY Change | 50.56% | 48.04% | 48.14% |
Intangibles | $722.8M | $743.4M | $764.0M |
YoY Change | 108.52% | 110.82% | 112.98% |
Long-Term Investments | $131.9M | $147.4M | $125.3M |
YoY Change | -67.46% | -66.92% | -69.91% |
Other Assets | $41.29M | $47.34M | $48.99M |
YoY Change | 2.88% | 16.36% | 61.9% |
Total Long-Term Assets | $1.029B | $1.070B | $1.071B |
YoY Change | 16.08% | 14.57% | 16.23% |
TOTAL ASSETS | |||
Total Short-Term Assets | $663.9M | $625.1M | $568.5M |
Total Long-Term Assets | $1.029B | $1.070B | $1.071B |
Total Assets | $1.693B | $1.695B | $1.640B |
YoY Change | 8.88% | 7.75% | 8.76% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $16.02M | $35.52M | $12.32M |
YoY Change | 75.51% | 391.33% | 106.97% |
Accrued Expenses | $110.3M | $133.0M | $89.43M |
YoY Change | 52.59% | 66.26% | 27.58% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $401.4M | $400.9M | $0.00 |
YoY Change | |||
Long-Term Debt Due | $401.4M | $400.9M | |
YoY Change | |||
Total Short-Term Liabilities | $726.0M | $735.5M | $284.6M |
YoY Change | 209.31% | 159.5% | 18.17% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $400.4M |
YoY Change | -100.0% | -100.0% | 4.13% |
Other Long-Term Liabilities | $10.37M | $11.97M | $14.15M |
YoY Change | -42.97% | -37.33% | -64.35% |
Total Long-Term Liabilities | $10.37M | $11.97M | $14.15M |
YoY Change | -42.97% | -37.33% | -64.35% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $726.0M | $735.5M | $284.6M |
Total Long-Term Liabilities | $10.37M | $11.97M | $14.15M |
Total Liabilities | $840.3M | $853.5M | $811.1M |
YoY Change | 12.86% | 8.39% | 7.71% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | $455.8M | $454.0M | $446.2M |
YoY Change | 20.74% | 27.56% | 34.3% |
Common Stock | $54.00K | $53.00K | $53.00K |
YoY Change | 1.89% | 0.0% | 0.0% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $852.8M | $841.4M | $828.4M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $1.693B | $1.695B | $1.640B |
YoY Change | 8.88% | 7.75% | 8.76% |
Cashflow Statement
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $1.749M | $7.865M | $25.62M |
YoY Change | -91.89% | -66.85% | 349.88% |
Depreciation, Depletion And Amortization | $21.78M | $21.56M | $21.36M |
YoY Change | 226.22% | 225.98% | 224.06% |
Cash From Operating Activities | $13.84M | $71.12M | $4.302M |
YoY Change | -436.76% | 53.69% | -88.12% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$147.0K | $576.0K | -$851.0K |
YoY Change | -70.42% | -7300.0% | -156.43% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$82.09M | -$16.26M | -$69.14M |
YoY Change | 1476.44% | -79.91% | -1.09% |
Cash From Investing Activities | -$82.23M | -$15.68M | -$69.99M |
YoY Change | 1341.65% | -80.63% | -2.04% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $866.0K | ||
YoY Change | -61.46% | ||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 6.455M | 2.273M | -$22.03M |
YoY Change | 387.54% | -18.71% | -1080.6% |
NET CHANGE | |||
Cash From Operating Activities | 13.84M | 71.12M | $4.302M |
Cash From Investing Activities | -82.23M | -15.68M | -$69.99M |
Cash From Financing Activities | 6.455M | 2.273M | -$22.03M |
Net Change In Cash | -61.94M | 57.71M | -$87.72M |
YoY Change | 629.52% | -281.09% | 165.83% |
FREE CASH FLOW | |||
Cash From Operating Activities | $13.84M | $71.12M | $4.302M |
Capital Expenditures | -$147.0K | $576.0K | -$851.0K |
Free Cash Flow | $13.99M | $70.54M | $5.153M |
YoY Change | -487.16% | 52.42% | -85.15% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-06-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
CY2021 | us-gaap |
Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
|
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member | |
CY2022Q2 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent | |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent | |
CY2022Q2 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2021Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent | |
CY2022Q2 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Entity File Number
EntityFileNumber
|
001-35518 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
20-2590184 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9715 Key West Avenue | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Rockville | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20850 | ||
dei |
City Area Code
CityAreaCode
|
301 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
838-2500 | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value per share | ||
CY2022Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
53495261 | shares |
dei |
Trading Symbol
TradingSymbol
|
SUPN | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
173428000 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
203434000 | usd |
CY2022Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
187359000 | usd |
CY2021Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
136246000 | usd |
CY2022Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
158063000 | usd |
CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
148932000 | usd |
CY2022Q2 | us-gaap |
Inventory Net
InventoryNet
|
84860000 | usd |
CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
85959000 | usd |
CY2022Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
21410000 | usd |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
27019000 | usd |
CY2022Q2 | us-gaap |
Assets Current
AssetsCurrent
|
625120000 | usd |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
601590000 | usd |
CY2022Q2 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
147373000 | usd |
CY2021Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
119166000 | usd |
CY2022Q2 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
16317000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
16955000 | usd |
CY2022Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
743405000 | usd |
CY2021Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
784693000 | usd |
CY2022Q2 | us-gaap |
Goodwill
Goodwill
|
115414000 | usd |
CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
117516000 | usd |
CY2022Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
47344000 | usd |
CY2021Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
49232000 | usd |
CY2022Q2 | us-gaap |
Assets
Assets
|
1694973000 | usd |
CY2021Q4 | us-gaap |
Assets
Assets
|
1689152000 | usd |
CY2022Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
133000000 | usd |
CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
117683000 | usd |
CY2022Q2 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
145761000 | usd |
CY2021Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
132724000 | usd |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
47240000 | usd |
CY2021Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
44840000 | usd |
CY2022Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
400909000 | usd |
CY2021Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | usd |
CY2022Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
8626000 | usd |
CY2021Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
20132000 | usd |
CY2022Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
735536000 | usd |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
315379000 | usd |
CY2022Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
0 | usd |
CY2021Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
379252000 | usd |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
9645000 | usd |
CY2021Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
35637000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
37080000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
41298000 | usd |
CY2022Q2 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
59313000 | usd |
CY2021Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
85355000 | usd |
CY2022Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
11965000 | usd |
CY2021Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
16380000 | usd |
CY2022Q2 | us-gaap |
Liabilities
Liabilities
|
853539000 | usd |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
873301000 | usd |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
53492386 | shares |
CY2022Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
53492386 | shares |
CY2022Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
53256094 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
53256094 | shares |
CY2022Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
53000 | usd |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
53000 | usd |
CY2022Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
389586000 | usd |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
434337000 | usd |
CY2022Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2220000 | usd |
CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
1539000 | usd |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
454015000 | usd |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
379922000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
841434000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
815851000 | usd |
CY2022Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1694973000 | usd |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1689152000 | usd |
CY2022Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
170051000 | usd |
CY2021Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
141329000 | usd |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
322557000 | usd | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
272261000 | usd | |
CY2022Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
20457000 | usd |
CY2021Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
25028000 | usd |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
38389000 | usd | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
39982000 | usd | |
CY2022Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
16385000 | usd |
CY2021Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15455000 | usd |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
37224000 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
49735000 | usd | |
CY2022Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
100476000 | usd |
CY2021Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
69535000 | usd |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
190935000 | usd | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
130992000 | usd | |
CY2022Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
20644000 | usd |
CY2021Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
5948000 | usd |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
41288000 | usd | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
11955000 | usd | |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
743000 | usd |
CY2021Q2 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-8750000 | usd |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
1408000 | usd | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-7730000 | usd | |
CY2022Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
158705000 | usd |
CY2021Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
107216000 | usd |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
309244000 | usd | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
224934000 | usd | |
CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
11346000 | usd |
CY2021Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
34113000 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
13313000 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
47327000 | usd | |
CY2022Q2 | us-gaap |
Interest Expense
InterestExpense
|
1810000 | usd |
CY2021Q2 | us-gaap |
Interest Expense
InterestExpense
|
5467000 | usd |
us-gaap |
Interest Expense
InterestExpense
|
3752000 | usd | |
us-gaap |
Interest Expense
InterestExpense
|
11564000 | usd | |
CY2022Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1788000 | usd |
CY2021Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2589000 | usd |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
16486000 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
6401000 | usd | |
CY2022Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-22000 | usd |
CY2021Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2878000 | usd |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
12734000 | usd | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5163000 | usd | |
CY2022Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
11324000 | usd |
CY2021Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
31235000 | usd |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
26047000 | usd | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
42164000 | usd | |
CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3459000 | usd |
CY2021Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7509000 | usd |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7434000 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12744000 | usd | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7865000 | usd |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
23726000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
33481000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
29420000 | usd | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.15 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.45 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.63 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.56 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.14 | |
CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.43 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.57 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.54 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53426163 | shares |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53005344 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53378319 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52985472 | shares | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61397159 | shares |
CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54724146 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61401694 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54601533 | shares | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7865000 | usd |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
23726000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
33481000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
29420000 | usd | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1447000 | usd |
CY2021Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-816000 | usd |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-3759000 | usd | |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-3542000 | usd | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1447000 | usd |
CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-816000 | usd |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-3759000 | usd | |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-3542000 | usd | |
CY2022Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
6418000 | usd |
CY2021Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
22910000 | usd |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
29722000 | usd | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
25878000 | usd | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
815851000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4025000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
866000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
25616000 | usd |
CY2022Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-2312000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
828446000 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4297000 | usd |
CY2022Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2273000 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7865000 | usd |
CY2022Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1447000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
841434000 | usd |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
744858000 | usd |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4371000 | usd |
CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2247000 | usd |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5694000 | usd |
CY2021Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-2726000 | usd |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
754444000 | usd |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5476000 | usd |
CY2021Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2749000 | usd |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
23726000 | usd |
CY2021Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-816000 | usd |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
785579000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
33481000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
29420000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
42919000 | usd | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13213000 | usd | |
us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | usd | |
us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
15000000 | usd | |
supn |
Payments For Proceeds From Collaborative Arrangement Investment
PaymentsForProceedsFromCollaborativeArrangementInvestment
|
12888000 | usd | |
supn |
Payments For Proceeds From Collaborative Arrangement Investment
PaymentsForProceedsFromCollaborativeArrangementInvestment
|
0 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
1053000 | usd | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
8632000 | usd | |
us-gaap |
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
|
13000 | usd | |
us-gaap |
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
|
219000 | usd | |
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-1068000 | usd | |
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
2371000 | usd | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
1408000 | usd | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-7730000 | usd | |
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
1187000 | usd | |
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
651000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8322000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9847000 | usd | |
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-16057000 | usd | |
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-2046000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
9093000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-3605000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-1842000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
7950000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1866000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
18003000 | usd | |
supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
13037000 | usd | |
supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
47406000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
11763000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-5679000 | usd | |
supn |
Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
|
-2100000 | usd | |
supn |
Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
|
0 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
82474000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
75421000 | usd | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
206503000 | usd | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
233272000 | usd | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
121112000 | usd | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
83844000 | usd | |
supn |
Payments To Acquire Property Plant And Equipment And Deferred Legal Fees
PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees
|
275000 | usd | |
supn |
Payments To Acquire Property Plant And Equipment And Deferred Legal Fees
PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees
|
1961000 | usd | |
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | usd | |
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
950000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-85666000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-152339000 | usd | |
us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
22900000 | usd | |
us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
0 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3139000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4996000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-19761000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4996000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-30006000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-64869000 | usd | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
203434000 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
288640000 | usd |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
173428000 | usd |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
223771000 | usd |
us-gaap |
Interest Paid Net
InterestPaidNet
|
1258000 | usd | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
1258000 | usd | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
8543000 | usd | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
20696000 | usd | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
6238000 | usd | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
4036000 | usd | |
supn |
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
|
212000 | usd | |
supn |
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
|
284000 | usd | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
580000 | usd | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | usd | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
Business Organization<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Products</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company launched Qelbree for adult patients in May 2022.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Osmolex ER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amantadine) extended-release is a once-daily product for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following: </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date in early October 2022 on the resubmitted new drug application (NDA).</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adamas Acquisition and Reorganization</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas Pharmaceuticals, Inc., a publicly-held pharmaceutical company (Adamas), pursuant to the Adamas Agreement dated October 10, 2021, and the Purchaser was merged with and into Adamas (the Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and Osmolex ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Tax (Benefit) Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of June 30, 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div> | ||
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div> | ||
CY2022Q2 | us-gaap |
Advertising Expense
AdvertisingExpense
|
36900000 | usd |
us-gaap |
Advertising Expense
AdvertisingExpense
|
60800000 | usd | |
us-gaap |
Advertising Expense
AdvertisingExpense
|
37100000 | usd | |
CY2021Q2 | us-gaap |
Advertising Expense
AdvertisingExpense
|
21800000 | usd |
CY2022Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
170051000 | usd |
CY2021Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
141329000 | usd |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
322557000 | usd | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
272261000 | usd | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
272261000 | usd | |
CY2022Q2 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
2500000 | usd |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
4700000 | usd | |
CY2021Q2 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
2200000 | usd |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
4400000 | usd | |
CY2022Q2 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
|
337637000 | usd |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
|
253301000 | usd |
CY2022Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
61000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2349000 | usd |
CY2022Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2966000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
238000 | usd |
CY2022Q2 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
334732000 | usd |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
255412000 | usd |
CY2022Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
187359000 | usd |
CY2022Q2 | supn |
Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
|
118457000 | usd |
CY2022Q2 | supn |
Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
|
28916000 | usd |
CY2022Q2 | supn |
Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
|
0 | usd |
CY2022Q2 | supn |
Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
|
0 | usd |
CY2022Q2 | us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
|
334732000 | usd |
us-gaap |
Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded
|
0 | usd | |
CY2021Q4 | us-gaap |
Proceeds From Divestiture Of Businesses And Interests In Affiliates
ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
|
12900000 | usd |
CY2021Q4 | us-gaap |
Proceeds From Divestiture Of Businesses And Interests In Affiliates
ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates
|
12900000 | usd |
CY2020Q2 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High
BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
|
230000000 | usd |
us-gaap |
Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
|
22900000 | usd | |
supn |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Excess Acquisition Date Fair Value
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue
|
2100000 | usd | |
CY2021Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
80477000 | usd |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
25000000 | usd | |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
1408000 | usd | |
CY2022Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
56885000 | usd |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
56885000 | usd |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
47240000 | usd |
CY2021Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
44840000 | usd |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
9645000 | usd |
CY2021Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
35637000 | usd |
CY2022Q2 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
56885000 | usd |
CY2021Q4 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
80477000 | usd |
CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
117516000 | usd |
us-gaap |
Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
|
-2102000 | usd | |
CY2022Q2 | us-gaap |
Goodwill
Goodwill
|
115414000 | usd |
us-gaap |
Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
|
P8Y2M1D | ||
CY2022Q2 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
848920000 | usd |
CY2022Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
105515000 | usd |
CY2022Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
743405000 | usd |
CY2021Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
848920000 | usd |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
64227000 | usd |
CY2021Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
784693000 | usd |
CY2022Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
79800000 | usd |
CY2022Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
79800000 | usd |
CY2022Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
75100000 | usd |
CY2018Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.91 | |
CY2022Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
74900000 | usd |
CY2022Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
73200000 | usd |
CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4297000 | usd |
CY2021Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5476000 | usd |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
8322000 | usd | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9847000 | usd | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
29420000 | usd | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53426163 | shares |
CY2022Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.91 | |
CY2022Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.91 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
7865000 | usd |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
23726000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
33481000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
29420000 | usd | |
CY2022Q2 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
888000 | usd |
CY2021Q2 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | usd |
us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
1775000 | usd | |
us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
0 | usd | |
CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
8753000 | usd |
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
23726000 | usd |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
35256000 | usd | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53005344 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53378319 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52985472 | shares | |
CY2022Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1187060 | shares |
CY2021Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1718802 | shares |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1239439 | shares | |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1616061 | shares | |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
6783936 | shares | |
CY2021Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
6783936 | shares | |
us-gaap |
Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
|
0 | shares | |
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61397159 | shares |
CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54724146 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61401694 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54601533 | shares | |
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.15 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.45 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.63 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.56 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.14 | |
CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.43 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.57 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.54 | ||
CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
3459000 | usd |
CY2021Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7509000 | usd |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7434000 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12744000 | usd | |
CY2022Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.305 | |
CY2021Q2 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.241 | |
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.285 | ||
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.302 | ||
CY2019Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P10Y | |
CY2021Q4 | supn |
Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
|
1 | renewaloption |
CY2021Q4 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
CY2022Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
30636000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
35365000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
30636000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
35365000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
7040000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6477000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
37080000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
41298000 | usd |
CY2022Q2 | supn |
Lease Liability
LeaseLiability
|
44120000 | usd |
CY2021Q4 | supn |
Lease Liability
LeaseLiability
|
47775000 | usd |
CY2022Q2 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
12600000 | usd |
CY2021Q4 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
13500000 | usd |
CY2022Q2 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
7463000 | usd |
CY2021Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
7325000 | usd |
CY2022Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
36860000 | usd |
CY2021Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
45711000 | usd |
CY2022Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
40537000 | usd |
CY2021Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
32923000 | usd |
CY2022Q2 | us-gaap |
Inventory Net
InventoryNet
|
84860000 | usd |
CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
85959000 | usd |
CY2022Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28524000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
33409000 | usd |
CY2022Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
12207000 | usd |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
16454000 | usd |
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
16317000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
16955000 | usd |
CY2022Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1400000 | usd | |
CY2021Q2 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1300000 | usd | |
CY2022Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
35518000 | usd |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
9331000 | usd |
CY2022Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
34256000 | usd |
CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
26728000 | usd |
CY2022Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14535000 | usd |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
28068000 | usd |
CY2022Q2 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
13352000 | usd |
CY2021Q4 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
18460000 | usd |
CY2022Q2 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
12020000 | usd |
CY2021Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
13821000 | usd |
CY2022Q2 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
8653000 | usd |
CY2021Q4 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
9125000 | usd |
CY2022Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
7040000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6477000 | usd |
CY2022Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
7626000 | usd |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5673000 | usd |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
133000000 | usd |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
117683000 | usd |
CY2022Q2 | supn |
Accrued Rebates
AccruedRebates
|
108648000 | usd |
CY2021Q4 | supn |
Accrued Rebates
AccruedRebates
|
97597000 | usd |
CY2022Q2 | supn |
Accrued Product Returns
AccruedProductReturns
|
37113000 | usd |
CY2021Q4 | supn |
Accrued Product Returns
AccruedProductReturns
|
35127000 | usd |
CY2022Q2 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
145761000 | usd |
CY2021Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
132724000 | usd |
CY2022Q2 | supn |
Non Recourse Liability Noncurrent
NonRecourseLiabilityNoncurrent
|
1364000 | usd |
CY2021Q4 | supn |
Non Recourse Liability Noncurrent
NonRecourseLiabilityNoncurrent
|
5977000 | usd |
CY2022Q2 | us-gaap |
Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
|
10601000 | usd |
CY2021Q4 | us-gaap |
Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
|
10403000 | usd |
CY2022Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
11965000 | usd |
CY2021Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
16380000 | usd |
CY2022Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1175000 | usd |
CY2021Q2 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
4498000 | usd |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
2330000 | usd | |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
9560000 | usd | |
CY2022Q2 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
635000 | usd |
CY2021Q2 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
969000 | usd |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
1422000 | usd | |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
2004000 | usd | |
CY2022Q2 | us-gaap |
Interest Expense
InterestExpense
|
1810000 | usd |
CY2021Q2 | us-gaap |
Interest Expense
InterestExpense
|
5467000 | usd |
us-gaap |
Interest Expense
InterestExpense
|
3752000 | usd | |
us-gaap |
Interest Expense
InterestExpense
|
11564000 | usd | |
CY2022Q2 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
500000 | usd |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
1100000 | usd | |
CY2021Q2 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4300000 | usd |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
8600000 | usd | |
CY2014Q3 | supn |
Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
|
30000000 | usd |